乳腺分泌性癌(secretory carcinoma of the breast, SCB)是一种罕见的乳腺恶性肿瘤,约占所有类型乳腺癌的0.02%,ETV6-NTRK3融合基因是其特征性基因改变。尽管多数情况下具有三阴表型,SCB通常预后良好,罕见复发、转移,但相关的分子基因...乳腺分泌性癌(secretory carcinoma of the breast, SCB)是一种罕见的乳腺恶性肿瘤,约占所有类型乳腺癌的0.02%,ETV6-NTRK3融合基因是其特征性基因改变。尽管多数情况下具有三阴表型,SCB通常预后良好,罕见复发、转移,但相关的分子基因组学改变仍未明确。本文报道了1例TERT启动子突变的复发SCB患者的临床资料、组织学特征、免疫表型及分子基因组学改变,并复习相关文献,从而加深对SCB的认识。展开更多
Mammary analogue secretory carcinoma (MASC) is a recently identified salivary tumor that shares morphological features of secretory carcinoma of the breast, salivary acinic cell carcinoma, low grade cystadenocarcinoma...Mammary analogue secretory carcinoma (MASC) is a recently identified salivary tumor that shares morphological features of secretory carcinoma of the breast, salivary acinic cell carcinoma, low grade cystadenocarcinoma and mucoepidermoid carcinoma. To date, a majority of cases have been reported in the major salivary glands with very few seen in the palate. We present 2 single institution cases of MASC of the soft palate to help further characterize this novel tumor.展开更多
Secretory carcinoma（SC）, previously described as mammary analogue secretory carcinoma（MASC）, is a recently described salivary gland tumor which morphologically resembles mammary secretory carcinoma. The first desc...Secretory carcinoma（SC）, previously described as mammary analogue secretory carcinoma（MASC）, is a recently described salivary gland tumor which morphologically resembles mammary secretory carcinoma. The first description of SC/MASC, reported by Skálová et al. in 2010, was as a rare salivary carcinoma imitating secretory carcinoma of the breast. SC/MASC is a unique salivary gland tumor with morphological overlap with acinic cell carcinoma（Aci CC）, mucoepidermoid carcinoma（MEC）, and adenocarcinoma not otherwise specified（ADCNOS）. SC/MASC shares similar clinicopathological features with Aci CC. As a critical difference between SC/MASC and Aci CC, SC/MASC characteristically has the chromosomal translocation t（12;15）（p13;q25） which leads to a fusion gene between the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15. This genetic background is an important differential diagnostic finding for excluding other salivary gland tumors and may be a critical factor determining the prognosis for patients with SC/MASC. Research in recent years has provided a large body of new data on SC/MASC and suggests the possibility that the ETV6-NTRK3 translocation could be a therapeutic target. Here, we review the morphological and clinicopathological features of SC/MASC and discuss new directions for therapy.展开更多
文摘乳腺分泌性癌(secretory carcinoma of the breast, SCB)是一种罕见的乳腺恶性肿瘤,约占所有类型乳腺癌的0.02%,ETV6-NTRK3融合基因是其特征性基因改变。尽管多数情况下具有三阴表型,SCB通常预后良好,罕见复发、转移,但相关的分子基因组学改变仍未明确。本文报道了1例TERT启动子突变的复发SCB患者的临床资料、组织学特征、免疫表型及分子基因组学改变,并复习相关文献,从而加深对SCB的认识。
文摘Mammary analogue secretory carcinoma (MASC) is a recently identified salivary tumor that shares morphological features of secretory carcinoma of the breast, salivary acinic cell carcinoma, low grade cystadenocarcinoma and mucoepidermoid carcinoma. To date, a majority of cases have been reported in the major salivary glands with very few seen in the palate. We present 2 single institution cases of MASC of the soft palate to help further characterize this novel tumor.
文摘Secretory carcinoma（SC）, previously described as mammary analogue secretory carcinoma（MASC）, is a recently described salivary gland tumor which morphologically resembles mammary secretory carcinoma. The first description of SC/MASC, reported by Skálová et al. in 2010, was as a rare salivary carcinoma imitating secretory carcinoma of the breast. SC/MASC is a unique salivary gland tumor with morphological overlap with acinic cell carcinoma（Aci CC）, mucoepidermoid carcinoma（MEC）, and adenocarcinoma not otherwise specified（ADCNOS）. SC/MASC shares similar clinicopathological features with Aci CC. As a critical difference between SC/MASC and Aci CC, SC/MASC characteristically has the chromosomal translocation t（12;15）（p13;q25） which leads to a fusion gene between the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15. This genetic background is an important differential diagnostic finding for excluding other salivary gland tumors and may be a critical factor determining the prognosis for patients with SC/MASC. Research in recent years has provided a large body of new data on SC/MASC and suggests the possibility that the ETV6-NTRK3 translocation could be a therapeutic target. Here, we review the morphological and clinicopathological features of SC/MASC and discuss new directions for therapy.
